Molecular Medicine | 卷:27 |
Possible inhibition of GM-CSF production by SARS-CoV-2 spike-based vaccines | |
Jianhua Li1  Ping Wang1  Kevin J. Tracey1  Haichao Wang1  | |
[1] The Feinstein Institutes for Medical Research, Northwell Health; | |
关键词: GM-CSF; SARS-CoV-2; Spike protein; Antibody; | |
DOI : 10.1186/s10020-021-00313-3 | |
来源: DOAJ |
【 摘 要 】
Abstract A SARS-like coronavirus 2 (SARS-CoV-2) has caused a pandemic Coronavirus Disease 2019 (COVID-19) that killed more than 3.3 million people worldwide. Like the SARS-CoV, SARS-CoV-2 also employs a receptor-binding motif (RBM) of its spike protein to bind a host receptor, the angiotensin-converting enzyme 2 (ACE2), to gain entry. Currently, several mRNA or adenoviral vaccines encoding for the spike protein of SARS-CoV-2 are being used to boost antibodies capable of inhibiting spike-ACE2 interaction and viral entry. However, recent evidence has also suggested an anti-inflammatory effect of spike-reactive antibodies, suggesting that some SARS-CoV-2 spike-based vaccines may elicit protective antibodies capable of inhibiting GM-CSF production and COVID-19 progression.
【 授权许可】
Unknown